Key Developments: Cempra Inc (CEMP.O)

CEMP.O on Nasdaq

21.61USD
26 Dec 2014
Price Change (% chg)

$0.95 (+4.60%)
Prev Close
$20.66
Open
$20.54
Day's High
$21.68
Day's Low
$20.48
Volume
464,691
Avg. Vol
469,176
52-wk High
$21.90
52-wk Low
$8.10

Search Stocks

Latest Key Developments (Source: Significant Developments)

Cempra Inc files for secondary public offerings
Tuesday, 18 Nov 2014 07:00pm EST 

Cempra Inc:Offers amount of $150,000,000 to be listed on Nasdaq National Market.  Full Article

Cempra Inc completes enrollment of solitaire-oral phase 3 trial
Thursday, 25 Sep 2014 04:05pm EDT 

Cempra Inc:Says completion of enrollment of the global Solitaire-Oral Phase 3 clinical trial of oral solithromycin in adult patients with moderate to moderately severe community-acquired bacterial pneumonia (CABP).Top-line efficacy and safety data are expected to be announced during the first quarter of 2015.  Full Article

Cempra Inc initiates phase 3 clinical trial in patients with uncomplicated gonorrhea infection
Tuesday, 12 Aug 2014 08:00am EDT 

Cempra Inc:Initiates Phase 3 Clinical Trial in Patients With Uncomplicated Gonorrhea Infection.Qualified Infectious Disease Product (QIDP) Granted for Solithromycin Capsules by FDA.Data from Single Study Expected to be Submitted at Same Time as Community Acquired Bacterial Pneumonia NDA.Announced the initiation of Phase 3 clinical trial, called Solitaire-U, of single 1000 mg dose of oral solithromycin in patients with uncomplicated Neisseria gonorrhea and chlamydia infections.Trial is being conducted in Australia and the U.S. and will enroll about 300 patients in a randomized 2-arm study with a single oral dose of 1000 mg of solithromycin compared with standard of care, 500 mg of ceftriaxone administered intramuscularly and 1000 mg of oral azithromycin.  Full Article

Cempra Inc Announces Partial Exercise of Over-Allotment Option and Completion of the Public Offering of Common Stock
Wednesday, 19 Jun 2013 04:04pm EDT 

Cempra Inc announced that underwritten public offering of 7,250,000 shares of common stock, plus an additional 1,023,938 shares issued pursuant to the partial exercise by the underwriters of their over-allotment option, at a public offering price of $7.00 per share. The partial exercise of the over-allotment option increases the net proceeds to the Company, after underwriting discounts and commissions and estimated offering expenses, from approximately $47.5 million to approximately $54.2 million. Barclays, Stifel and Cowen and Company are acting as joint book-running managers for the offering. Needham & Company and SunTrust Robinson Humphrey are acting as co-managers.  Full Article

Cempra Inc Prices Public Offering of Common Stock
Friday, 14 Jun 2013 09:29am EDT 

Cempra Inc announced that it has priced an underwritten public offering of 7,250,000 shares of its common stock at a price of $7.00 per share for aggregate gross proceeds of $50.8 million. Net proceeds after underwriting discounts and commissions and expenses of the offering are expected to be approximately $47.7 million. The Company also has granted the underwriters a 30-day option to purchase up to an additional 1,087,500 shares to cover over-allotments, if any, which would result in additional net proceeds of approximately $7.2 million, if exercised in full. The offering is expected to close on or about June 19, 2013, subject to satisfaction of customary closing conditions. Barclays, Stifel and Cowen and Company are acting as joint book-running managers for the offering. Needham & Company and SunTrust Robinson Humphrey are acting as co-managers.  Full Article

Cempra Inc Announces Proposed Public Offering of Common Stock
Thursday, 13 Jun 2013 04:01pm EDT 

Cempra Inc announced that its intention to offer and sell shares of its common stock in an underwritten public offering pursuant to its existing shelf registration statement. The Company also intends to grant to the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock sold in the public offering to cover over-allotments, if any. The Company intends to use the net proceeds from the offering to fund its planned IV-to-oral Phase 3 clinical trial of solithromycin in community acquired bacterial pneumonia (CABP), working capital and general corporate and administrative expenses. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Barclays, Stifel and Cowen and Company are acting as joint book-running managers for the offering.  Full Article

Cempra Inc Secures $58 Million Contract To Develop Antibiotic For Pediatric Use And Biodefense By Biomedical Advanced Research And Development Authority
Tuesday, 28 May 2013 09:15am EDT 

Cempra Inc announced that the Biomedical Advanced Research and Development Authority ( BARDA ) has awarded Cempra with a five year contract valued up to $58 million for the development of solithromycin to treat infections in pediatric populations and for the treatment of infections by bioterror threat pathogens. Solithromycin, Cempra's lead product candidate, is a fourth generation macrolide antibiotic in the fluoroketolide family that is currently in Phase 3 development for community-acquired bacterial pneumonia (CABP) in adults.  Full Article

Cempra Inc Signs Japan Licensing Deal For New Antibiotic-DJ
Monday, 13 May 2013 07:55pm EDT 

Dow Jones reported that Cempra Inc signed an agreement giving a unit of Fujifilm Holdings Corp. the right to brings its new antibiotic to market in Japan. The Company will receive an upfront payment of $10 million and milestone payments of up to $60 million from Toyoma Chemical Co. Cempra also expects to receive royalties based on the sales of the antibiotic, solithromycin, following its launch in Japan.  Full Article

Antibiotic developer Cempra's CEO says not looking for a buyer

- Cempra Inc has no plans for now to sell itself, its CEO said, brushing off talk that the company is a potential target as big drugmakers set their sights on antibiotic developers.

Search Stocks